

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Vemurafenib for the treatment of unresectable locally advanced or metastatic, BRAF^{V600} mutation positive malignant melanoma

Please sign and return to:

Marcia Miller, Technology Appraisal Administrator
Email: TACommA@nice.org.uk Fax: +44 (0)20 7061 9721
Post: NICE, MidCity Place, 71 High Holborn, London, WC1V 6NA

I confirm that:

- I agree with the content of the statement submitted by RCP and consequently I will not be submitting a personal statement.

Name: CAUL LORIGAO

Signed: 

Date: 22 Feb 2012